Launched in 2017, the Coalition for Epidemic Preparedness Innovations (CEPI) is an international coalition of governments, academic, philanthropic, private, public, and intergovernmental institutions whose vision is to create a world in which epidemics and pandemics are no longer a threat to humanity. Our mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. CEPI played a central role in the global response to COVID-19, creating the world’s largest portfolio of COVID-19 vaccines – seven of which are approved for global or domestic use - and co-leading COVAX, the global initiative to support equitable access which supported the delivery of over 2bn vaccine doses globally. CEPI has CEPI has contributed to a number of scientific breakthroughs in vaccine development against other infectious diseases, including the first ever licensed Chikungunya vaccine and the first Nipah and Lassa virus vaccines into Phase 1 trials.
As COVID-19 has demonstrated, emerging infectious diseases represent an existential threat to our way of life. COVID-19 is not the first pandemic of the 21st century, and unless we act now, we can be sure that it will not be the last. Unlike some of the other big threats that humanity faces, we have the tools to systematically reduce and even eliminate the risk of future pandemics. It is vital that we capitalise on the rare alignment of political will, practical experience, and technical and scientific progress emerging from the pandemic to prevent such devastation happening again. CEPI’s five-year plan for 2022-2026 – known as CEPI 2.0 - aims to dramatically reduce or even eliminate the future risk of pandemics and epidemics. Central to the plan is CEPI’s goal to accelerate the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days. Achieving this ‘100 Days Mission’, which has been embraced by the G7 and G20, would give the world a fighting chance of containing a future outbreak before it can spread to become a global pandemic, potentially averting millions of deaths and trillions of dollars in economic damage.
CEPI is a not-for-profit association under Norwegian Law and has offices in Oslo (HQ), London, and Washington DC.
In CEPI we strive for diverse thinking, and we want a diverse pool of candidates for all our vacancies. We work for an inclusive working environment where each employee can contribute and grow.
More details about CEPI and our mission can be found on our website: www.cepi.net

CEPI is currently looking for a Vaccine Manufacturing Lead to join the Manufacturing & Supply Chain (MSC) division within the Manufacturing & Supply Chain Networks team.
Objectives
1. Deliver activities that help secure operational sustainability across the CEPI Vaccine Manufacturing Facility Network (VMFN) supporting CEPI’s projects with agile, robust, rapid equitable access solutions for vaccine production in Global South/LMIC regions.
2. Work with VMFN organisations to enable their outbreak response preparedness and future supply of CEPI vaccines portfolio to emerging disease threats leveraging novel platforms/innovations to reach the CEPI 100DM, in collaboration with global stakeholders and partners.

• Lead vaccine manufacturing operational sustainability project activities with CEPI VMFN organisations in Lat Am and Caribbean, Africa, M. East, S.E. Asia &/or W. Pacific.
• Drive scientific-technical-manufacturing programs to achieve future sustainability across a range of vaccine platforms supporting productivity, quality, and equitable supply in Global South/LMIC regions.
• Manage collaborative relationships with international partners, providing input to execute and maintain vaccine manufacture sustainability deliverables with CEPI VMFN organisations in each region.
• Support CEPI VMFN due diligence processes and site-visits/meetings.
• Engage with local and international organisations e.g., RVMC, WHO, PAHO, Africa-CDC, ASEAN to advance CEPI vaccine manufacturing sustainability deliverables with each facility.
• Play a key role in defining and delivering long-term strategic goals with VMFN organisations and partners within each region – coordinating activities across CEPI internal teams and external partners, collaborators, and stakeholders.

• Master’s degree &/or Ph D in Biochemical Engineering, Biological/Pharmaceutical sciences, or another relevant discipline.
• At least 10-years’ experience in the vaccines industry, consulting or in an NGO (e.g. WHO) is essential - public health sector acceptable, biologics experience considered.
• Demonstrated leadership of diverse teams to integrate technical, quality, regulatory compliance, and operational elements towards managing vaccine manufacturing site readiness.
• Expertise across vaccine development, (drug substance/product) manufacture, testing, formulation, fill, release and supply for clinical trial or commercial use preferably within LMIC regions.
• Expertise in biopharma organisation, evaluation, technology transfer and facility due diligence.
• Managing licensed third party CDMO relationships.
• Experience working across cultures and countries is preferred.
• Prior interactions with National Regulatory Agencies considered advantageous.
• Fluency in verbal-written English is a must and exceptional communication skills are required.

• This position can be based in the UK, US or Norway.
Travel to other countries &/or regions is estimated to require
• 20% of time.

• Experience in the international effort on developing vaccines against emerging infectious diseases and accelerating vaccine development response to outbreaks
• The opportunity to work together with leading internal and external experts on solutions for global challenges
• A diverse and inclusive working environment

Background verification will be conducted to verify information provided in the CV and available documentation for the successful candidate.